Edgewise Therapeutics, Inc.
EWTX
Kedudukan dalam Saham
#3981
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Harga Saham
$38.12
Modal Pasaran
$4.10B
Perubahan (1 hari)
2.50%
Perubahan (1 tahun)
153.12%
Negara
US
Perdagangan Edgewise Therapeutics, Inc. (EWTX)
Kategori
Healthcare
Pendapatan untuk Edgewise Therapeutics, Inc. (EWTX)
Pendapatan pada Jun 2026 TTM: $-197.22M
Menurut laporan kewangan terkini Edgewise Therapeutics, Inc., pendapatan semasa syarikat ialah $-197.22M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-100.16M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-67.64M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Edgewise Therapeutics, Inc. dari 2019 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-197.22M | 47.39% |
| 2024 | $-133.81M | 33.60% |
| 2023 | $-100.16M | 48.08% |
| 2022 | $-67.64M | 57.99% |
| 2021 | $-42.81M | 150.03% |
| 2020 | $-17.12M | 76.43% |
| 2019 | $-9.71M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -2,774.60% |
US
|
|
| $-3.09B | 1,465.24% |
US
|
|
| $-4.02B | 1,936.38% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,089.06% |
NL
|
